Source: BioPortfolio

Genentech: New Data Demonstrate the Continued Clinical Benefit of Fixedduration Chemotherapyfree Venclextabased Treatments in Chronic Lymphocytic Leukemia

In an updated analysis of the CLL14 study Venclexta plus Gazyva achieved remissions that were sustained over time in people with previously untreated chronic lymphocytic leukemia At fouryear followup of the MURANO study Venclexta plus Rituxan continued t...

Read full article »

Top Competitors or Alternatives

Missing a competitor? Contribute!

Estimated Annual Revenue

Estimated Employees

Alexander Hardy's photo - CEO of Genentech

CEO

Alexander Hardy

CEO Approval Rating

69/100

Genentech is a biotechnology company that discovers, develops and commercializes medicines to treat patients with life-t... Read more